Impetigo

$185+ million in incremental orders for ACAM2000® and VIGIV to be delivered in 2024 and 2025GAITHERSBURG, Md., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured approximately $400 million in orders in 2024 and 2025 associated with its vaccinia, smallpox and mpox product portfolio. This includes the previously disclosed U.S. government contract modification to procure ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live), as well as CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) contract options exercised in 2023 and 2024. To date in 2024, customer orders of nearly $210 million have been delivered for ACAM2000® and VIGIV. For the remainder of 2024 and into 2025, Emergent is confirmed to deliver an incremental $185+ million in ACAM2000® and VIGIV orders. “Emergent continues to be a trusted partner to supply medical countermeasures for biodefense and global health preparedness, and these incremental orders demonstrate our ongoing leadership to help address serious viral threats like smallpox and mpox,” said Joe Papa, president and CEO of Emergent. “As a leader in public health preparedness for 25 years, we recognize that the world is increasingly dangerous, and we believe our products, services and overall capabilities are critical to safeguarding communities against potential public health outbreaks.” Emergent is actively involved in playing its part in addressing the ongoing mpox outbreak. In August, the U.S. Food and Drug Administration approved an update for ACAM2000® to include prevention of mpox disease in individuals determined to be at high risk for mpox infection in its label, in addition to the previously approved smallpox indication. Shortly after achieving this regulatory milestone, Emergent announced that it submitted an Expression of Interest for ACAM2000® vaccine to be assessed for Emergency Use Listing (EUL) with the World Health Organization (WHO). This was in response to the WHO’s invitation for mpox vaccine manufacturers to submit dossiers for EUL evaluation. Emergent is currently in discussions with the WHO surrounding next steps for a potential EUL or Prequalification submission for ACAM2000®. The EUL/Prequalification process is part of the WHO’s broader efforts to support the mpox outbreak response and is a prerequisite of the recent and related UNICEF emergency tender. In furtherance of its commitment to support mpox response efforts, Emergent has donated 50,000 doses of ACAM2000® for potential deployment across impacted countries across the African continent. About ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live)ACAM2000® is indicated in the U.S. for active immunization for the prevention of smallpox and mpox disease in individuals determined to be at high risk for smallpox and mpox infection. The labeling for ACAM2000® contains a contraindication for individuals with severe immunodeficiency. Severe localized or systemic infection with vaccinia (progressive vaccinia) may occur in persons with weakened immune systems. Individuals with severe immunodeficiency who are not expected to benefit from the vaccine should not receive ACAM2000®. The risk for experiencing severe vaccination complications must be weighed against the risk for experiencing a potentially severe or fatal smallpox or mpox infection. Additionally, there are warnings and precautions for myocarditis, pericarditis, encephalitis, encephalomyelitis, encephalopathy, progressive vaccinia, generalized vaccinia, severe vaccinial skin infections, erythema multiforme major (including Stevens-Johnson Syndrome), eczema vaccinatum resulting in permanent sequelae or death, accidental eye infection (ocular vaccinia), which can cause ocular complications that may lead to blindness, and fetal death. These may occur following either primary vaccination or revaccination with live vaccinia virus vaccines, including ACAM2000®. These risks are increased in certain individuals and may result in severe disability, permanent neurological sequalae and/or death. Please see the full Prescribing Information for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Vaccine for full Boxed Warning and additional safety information. About CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV)(See full prescribing information for complete boxed warning) WARNING: INTERACTIONS WITH GLUCOSE MONITORING SYSTEMSBlood glucose measurement in patients receiving Vaccinia Immune Globulin Intravenous (Human) (VIGIV) must be done with a glucose-specific method (monitor and test strips) to avoid interference by maltose contained in VIGIV. Maltose in IGIV products may give falsely high blood glucose levels in certain types of blood glucose testing systems (for example those based on the GDH-PQQ or glucose-dye-oxidoreductase methods) resulting in inappropriate administration of insulin and life-threatening hypoglycemia. Cases of true hypoglycemia may go untreated if the hypoglycemic state is masked by falsely elevated glucose readings. Carefully review the product information of the blood glucose testing system, including that of the test strips, to determine if the system is appropriate for use with maltose-containing parenteral products. VIGIV (vaccinia immune globulin intravenous, human) is an Immune Globulin (Human), 5% Liquid, indicated for the treatment of complications due to vaccinia vaccination. VIGIV is indicated for the treatment, and/or modification of the following conditions: eczema vaccinatum; progressive vaccinia; severe generalized vaccinia; vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy; or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions; and aberrant infections induced by vaccinia virus that include its accidental implantation in eyes (except in cases of isolated keratitis), mouth, or other areas where vaccinia infection would constitute a special hazard. VIGIV is not considered to be effective in the treatment of postvaccinial encephalitis. VIGIV is contraindicated in: isolated vaccinia keratitis; Individuals with a history of anaphylaxis or prior severe systemic reaction associated with the parenteral administration of this or other human immune globulin preparations; IgA-deficient patients with antibodies against IgA and a history of IgA hypersensitivity, as it contains trace amounts of IgA (40 mcg/mL).Warnings and Precautions for VIGIV include: Hypersensitivity to human immune globulin (acute anaphylaxis)Acute renal dysfunction/failure. Use VIGIV with caution in patients with pre-existing renal insufficiency and in patients at increased risk of developing renal insufficiency.Thrombosis may occur with immune globulin products, including VIGIV. For patients at risk of thrombosis, administer VIGIV at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.Hemolysis or hemolytic anemiaAseptic meningitis syndrome (AMS)Noncardiogenic pulmonary edema [Transfusion-Related Acute Lung Injury (TRALI)]Transmission of infectious agents from human plasmaMonitor renal function and urine output in patients at risk of renal failure; check baseline blood viscosity in patients at risk of hyperviscosity; and conduct confirmatory tests if hemolysis or TRALI is suspected.Blood glucose monitoring There is no human or animal data for use of VIGIV during pregnancy. VIGIV should only be given to pregnant and nursing women if the potential benefits outweigh the potential risks. It is not known whether VIGIV is excreted in human milk. The safety and efficacy of VIGIV has not been established in pediatric and geriatric populations. The most frequently reported adverse reactions to VIGIV treatment in clinical trials (>10%) include: headache, nausea, rigors, and dizziness. Please see full Prescribing Information for VIGIV for additional safety information. About Emergent BioSolutionsAt Emergent, our mission is to protect and enhance life. For 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. Safe Harbor StatementThis communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the supply and expected timing for delivery of the ACAM2000® and VIGIV, Emergent’s ability to increase inventories of ACAM2000® and VIGIV to meet requested levels within specified time frames, if needed, the discussions with the WHO regarding Emergent’s EUL or Prequalification submission for ACAM2000®, and the WHO’s assessment of such submission and related UNICEF emergency tender, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “intend,” “may,” “plan,” “position,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statement speaks only as of the date of this communication and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances. There are a number of important factors that could cause our actual results to differ materially from those indicated by any forward-looking statements. Readers should consider this cautionary statement, as well as the risk factors and other disclosures included in our periodic reports filed with the Securities and Exchange Commission, when evaluating our forward-looking statements. Investor Contact:Richard S. LindahlExecutive Vice President, CFOlindahlr@ebsi.com Media Contact:Assal HellmerVice President, Communicationsmediarelations@ebsi.com

The move was made to help free up access to care for patients across pharmacies and dental practices and to give patients faster, simpler and fairer access to primary care. This article follows on from a story published in OSP ​ about how pharmacists will be able to intervene to help identify people at risk of liver disease. We asked some experts what they thought about more power being handed over and whether it would become burdensome. Stefano Mirabello is a pharmacist at NowPatient ​. He said: “Pharmacies and pharmacists often find themselves facing increased demands and workloads, especially due to overall strains being placed on the NHS and wait times. Many people will visit their local pharmacy for medical advice rather than wait for a GP appointment. Pharmacists can offer help and advice on a range of conditions such as shingles, impetigo and UTIs, already doing their part in primary care and taking the strain off of GPs and doctors. “They can acknowledge if symptoms can be eased through a course of prescription medication or whether the issue should be escalated to a GP or doctor. However, it is important to acknowledge that funding is crucial in this growing demand. Pharmacists are already stretched thin in their profession and capacity must be considered, so additional support would be beneficial if they are to widen their scope of service.” Tara Thompson vice president of clinical services at Revelation Pharma ​. She works in the US and is a compounding pharmacist and patient advocate with 11 years’ experience in sterile and nonsterile compounding at Innovation Compounding and Revelation Pharma. googletag.cmd.push(function () { googletag.display('text-ad1'); }); Tara said: “As the experts in drug formulation and interaction, trained in chemistry and the pharmacokinetics and therapeutics behind medicine and drug delivery systems in both the human and animal body, pharmacists have one of the highest levels of insight when it comes to achieving optimal patient health. The pairing of patient-first advocacy with unique prescription understanding makes an increased level of power for pharmacists not just important, but natural. “Frequency is also a significant factor that plays into the argument for increased power for pharmacists. Patients typically see their pharmacist eight times per year (versus only seeing their prescribers 1-2 times per year), which puts them at the forefront of public health. Pharmacists are frequently first in line as patients’ healthcare information sources.” She explained that a patient leans on a pharmacist to receive the highest level of education around their prescriptions, trusts in their ability for proper filling and in making sure counterindications are understood. “In the end, pharmacists possess extensive knowledge like no other in drug-drug, drug-food, and other interactions, as well as drug level monitoring, not to mention pharmacovigilance - preventing adverse drug reactions - and drug shortage options. This all-inclusive expertise supports healthcare providers and prescribers in delivering comprehensive patient care,” she added. Hussain Ahmad has more than 10 years of experience working with patients across Europe and, most recently, in the North of England. He is an experienced hospital doctor working primarily in A&E in the North West and has helped COVID patients who have been admitted to hospital. He currently prescribes for Click2Pharmacy ​. He said: “Pharmacists are a much more accessible option for blood tests to screen for liver conditions. Currently, we do offer these tests but they are privately funded and not available on the NHS. If our tests show any abnormal results, we refer to their GP to arrange an ultrasound, as this is not a service we provide. Depending on the results, we advise patients on lifestyle changes to lower their cholesterol or lose weight to support liver health. “If this service were to be funded by the NHS, there is a concern that this increased demand could stretch our resources, so this would need to be carefully managed to ensure pharmacists aren't overloaded and patient care remains a high priority. While we can perform initial screenings and refer patients as needed, more complex diagnostics and treatments would still need to be handled by GPs.”

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than $250 million in contract modifications from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services (HHS), to deliver millions of doses of four medical countermeasures (MCMs). These contract modifications will help ensure continued supply/stockpiling of critical MCMs to address biological threats and emergencies against anthrax, smallpox and botulism. The four awards include: A contract modification valued at $30.0 million to supply CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) this year. Previously known as AV7909, CYFENDUS® is a two-dose anthrax vaccine for post-exposure prophylaxis use in individuals 18 years of age and older. This new procurement funding is from Emergent’s existing 10-year contract with the Biomedical Advanced Research and Development Authority (BARDA) under contract (HHSO100201600030C).A contract modification valued at $99.9 million to supply ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) this year. ACAM2000® is licensed for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection. This is under Emergent’s existing 10-year contract with ASPR (75A50119C00071).Two new contract options totaling $122.9 million have been awarded to supply ASPR with VIGIV® [Vaccinia Immune Globulin Intravenous (Human)] drug product, and BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] drug substance and delivery of drug production this year and into early 2025. VIGIV® is used for treatment of complications to smallpox vaccination, while BAT® is indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients. Both are under Emergent’s existing 10-year contracts with ASPR (75A50119C00037 and 75A50119C00075, respectively). “Securing multiple contract modifications with the U.S. government for our medical countermeasure products affirms that Emergent is a trusted biodefense partner, and also demonstrates the strength and sustainment of our product portfolio,” said Paul Williams, senior vice president, products head at Emergent. “As part of our longstanding public-private partnership, we stand ready to continue fulfilling preparedness priorities and stockpiling efforts in the U.S. and abroad.” Emergent specializes in developing, manufacturing, and supplying MCMs for military and civilian populations. The types and quantities of products that should be maintained in a stockpile will depend on the population requiring protection, the products available for meeting the threat, as well as government resources and priorities. About CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) Indication CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) is a vaccine indicated for post-exposure prophylaxis of anthrax disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when given with recommended antibacterial drugs. The efficacy of CYFENDUS® vaccine for post-exposure prophylaxis (PEP) is based solely on studies in animal models of inhalational anthrax. Important Safety Information Contraindication: Do not take CYFENDUS® vaccine if you are allergic to CYFENDUS® vaccine, BioThrax® (Anthrax Vaccine Adsorbed) or any ingredient of the vaccine. Allergic reactions: Appropriate medical treatment and supervision must be available after receiving CYFENDUS® vaccine to manage possible serious allergic reactions. Get medical help right away if you have any symptoms of a serious allergic reaction. Altered Immunocompetence: Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished immune response to CYFENDUS® vaccine. Pregnancy: CYFENDUS® vaccine can cause fetal harm when administered to a pregnant individual. Before getting CYFENDUS® vaccine, tell your healthcare provider if you may be pregnant, plan to get pregnant soon, or are nursing a baby. Adverse reactions: The most common adverse reactions reported were tenderness, pain, warmth, itching, swelling, redness, bruising, arm motion limitations, muscle aches, tiredness, headache, and fever. U.S. Prescribing InformationThe full Prescribing Information for CYFENDUS® vaccine can be found here. About ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) ACAM2000® is the primary smallpox vaccine designated for use in a bioterrorism emergency, with doses having been supplied to the U.S. Strategic National Stockpile. ACAM2000® is also licensed in Australia and Singapore and is currently stockpiled both in the U.S. and internationally. ACAM2000® is indicated for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection. The labeling for ACAM2000® contains a contraindication for individuals with severe immunodeficiency. Severe localized or systemic infection with vaccinia (progressive vaccinia) may occur in persons with weakened immune systems. Individuals with severe immunodeficiency who are not expected to benefit from the vaccine should not receive ACAM2000®. The risk for experiencing severe vaccination complications must be weighed against the risk for experiencing a potentially fatal smallpox infection. Additionally, there are warnings and precautions for myocarditis, pericarditis, encephalitis, encephalomyelitis, encephalopathy, generalized vaccinia, severe vaccinial skin infections, erythema multiforme major (including Stevens-Johnson Syndrome), eczema vaccinatum resulting in permanent sequelae or death, ocular complications; blindness and fetal death have occurred following either primary vaccination or revaccination with live vaccinia virus smallpox vaccines. These risks are increased in certain individuals and may result in severe disability, permanent neurological sequalae and/or death. Please see full Prescribing Information for full Boxed Warning and additional safety information. About VIGIV® [Vaccinia Immune Globulin Intravenous (Human)](See full prescribing information for complete boxed warning) WARNING: INTERACTIONS WITH GLUCOSE MONITORING SYSTEMSBlood glucose measurement in patients receiving Vaccinia Immune Globulin Intravenous (Human) (VIGIV) must be done with a glucose-specific method (monitor and test strips) to avoid interference by maltose contained in VIGIV. Maltose in IGIV products may give falsely high blood glucose levels in certain types of blood glucose testing systems (for example those based on the GDH-PQQ or glucose-dye-oxidoreductase methods) resulting in inappropriate administration of insulin and life-threatening hypoglycemia. Cases of true hypoglycemia may go untreated if the hypoglycemic state is masked by falsely elevated glucose readings. Carefully review the product information of the blood glucose testing system, including that of the test strips, to determine if the system is appropriate for use with maltose-containing parenteral products. VIGIV (vaccinia immune globulin intravenous, human) is an Immune Globulin (Human), 5% Liquid, indicated for the treatment and/or modification of the following conditions: eczema vaccinatum; progressive vaccinia; severe generalized vaccinia; vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy; or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions; and aberrant infections induced by vaccinia virus that include its accidental implantation in eyes (except in cases of isolated keratitis), mouth, or other areas where vaccinia infection would constitute a special hazard.VIGIV is not considered to be effective in the treatment of postvaccinial encephalitis. VIGIV is contraindicated in: isolated vaccinia keratitis; Individuals with a history of anaphylaxis or prior severe systemic reaction associated with the parenteral administration of this or other human immune globulin preparations; IgA-deficient patients with antibodies against IgA and a history of IgA hypersensitivity, as it contains trace amounts of IgA (40 mcg/mL). Warnings and Precautions for VIGIV include: Hypersensitivity to human immune globulin (acute anaphylaxis)Acute renal dysfunction/failure. Use VIGIV with caution in patients with pre-existing renal insufficiency and in patients at increased risk of developing renal insufficiency.Thrombosis may occur with immune globulin products, including VIGIV. For patients at risk of thrombosis, administer VIGIV at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.Hemolysis or hemolytic anemiaAseptic meningitis syndrome (AMS)Noncardiogenic pulmonary edema [Transfusion-Related Acute Lung Injury (TRALI)]Transmission of infectious agents from human plasmaMonitor renal function and urine output in patients at risk of renal failure; check baseline blood viscosity in patients at risk of hyperviscosity; and conduct confirmatory tests if hemolysis or TRALI is suspected.Blood glucose monitoring There is no human or animal data for use of VIGIV during pregnancy. VIGIV should only be given to pregnant and nursing women if the potential benefits outweigh the potential risks. It is not known whether VIGIV is excreted in human milk. The safety and efficacy of VIGIV has not been established in pediatric and geriatric populations. The most frequently reported adverse reactions to VIGIV treatment in clinical trials (>10%) include: headache, nausea, rigors, and dizziness. Please see full Prescribing Information for VIGIV for additional safety information. About BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] BAT® is a mixture of immune globulin fragments indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients. The effectiveness of BAT is based solely on efficacy studies conducted in animal models of botulism. The Warnings and Precautions for BAT include: Severe hypersensitivity reactions, including anaphylaxis, as well as delayed allergic reactions, including serum sickness may occur following BAT administration. Prepare for monitoring and management of allergic reactions. Infusion reactions. These reactions may be related to the infusion rate of BAT.Interference with blood glucose testing. Because BAT contains maltose, interference with non-glucose specific blood sugar testing systems can occur. Use glucose-specific testing systems.Transmissible infections agents. BAT is made from equine plasma and may contain infectious agents, e.g. viruses. There is no human or animal data for use of BAT during pregnancy. BAT should only be given to pregnant and nursing women if the potential benefits outweigh the potential risks. It is not known whether BAT is excreted in human milk. The safety and efficacy of BAT has not been established in pediatric and geriatric populations. Only limited safety data exists for pediatric populations. The most common adverse reactions observed in ≥5% of healthy volunteers in clinical trials were headache, nausea, pruritus, and urticaria. The most common adverse reactions reported in ≥1% of patients in a clinical study were pyrexia, rash, chills, nausea, and edema. One serious adverse reaction of hemodynamic instability was observed in one patient in the clinical study. Please see full Prescribing Information for BAT for additional safety information. About Emergent BioSolutions At Emergent, our mission is to protect and enhance life. For 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. Safe Harbor StatementThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the development, availability, and government procurement of ACAM2000® vaccine, CYFENDUS® vaccine, BAT® and VIGIV® are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “should,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs, and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events, or circumstances. Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements. Investor Contact:Richard S. LindahlExecutive Vice President, CFOlindahlr@ebsi.com Media Contact:Assal HellmerVice President, Communicationsmediarelations@ebsi.com